Delayed immune-related events (DIRE) after discontinuation of immunotherapy: diagnostic hazard of autoimmunity at a distance
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Delayed immune-related events (DIRE) after discontinuation of immunotherapy: diagnostic hazard of autoimmunity at a distance
Authors
Keywords
Immunotherapy, Checkpoint inhibitor, Costimulatory agonist, Delayed toxicity, Immune-related adverse events
Journal
Journal for ImmunoTherapy of Cancer
Volume 7, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2019-07-03
DOI
10.1186/s40425-019-0645-6
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- What do we know about cancer immunotherapy? Long-term survival and immune-related adverse events
- (2018) Jesus Miranda Poma et al. ALLERGOLOGIA ET IMMUNOPATHOLOGIA
- Nivolumab versus docetaxel in previously treated advanced non-small-cell lung cancer (CheckMate 017 and CheckMate 057): 3-year update and outcomes in patients with liver metastases
- (2018) E E Vokes et al. ANNALS OF ONCOLOGY
- Neurological Adverse Events Associated with Immune Checkpoint Inhibitors: Diagnosis and Management
- (2018) Christophoros Astaras et al. Current Neurology and Neuroscience Reports
- Optimal management of immune-related adverse events resulting from treatment with immune checkpoint inhibitors: a review and update
- (2018) Hiroki Nagai et al. International Journal of Clinical Oncology
- Myasthenia gravis and Guillain-Barré syndrome adverse events with immune checkpoint inhibitors.
- (2018) Catherine R. Garcia et al. JOURNAL OF CLINICAL ONCOLOGY
- Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
- (2018) Julie R. Brahmer et al. JOURNAL OF CLINICAL ONCOLOGY
- Immune Checkpoint Inhibitor Toxicity Review for the Palliative Care Clinician
- (2018) Eric D. Hansen et al. JOURNAL OF PAIN AND SYMPTOM MANAGEMENT
- New NCCN Guidelines: Recognition and Management of Immunotherapy-Related Toxicity
- (2018) John A. Thompson Journal of the National Comprehensive Cancer Network
- Adverse Events Associated with Immune Checkpoint Blockade
- (2018) NEW ENGLAND JOURNAL OF MEDICINE
- Neoadjuvant PD-1 Blockade in Resectable Lung Cancer
- (2018) Patrick M. Forde et al. NEW ENGLAND JOURNAL OF MEDICINE
- Delayed Autoimmune Toxicity Occurring Several Months After Cessation of Anti‐PD‐1 Therapy
- (2018) Sagun Parakh et al. ONCOLOGIST
- A Case of Nivolumab‐Induced Bullous Pemphigoid: Review of Dermatologic Toxicity Associated with Programmed Cell Death Protein‐1/Programmed Death Ligand‐1 Inhibitors and Recommendations for Diagnosis and Management
- (2018) Adriana T. Lopez et al. ONCOLOGIST
- Myositis as an adverse event of immune checkpoint blockade for cancer therapy
- (2018) Mohsin Shah et al. SEMINARS IN ARTHRITIS AND RHEUMATISM
- Timing of Onset of Adverse Cutaneous Reactions Associated With Programmed Cell Death Protein 1 Inhibitor Therapy
- (2018) Leo L. Wang et al. JAMA Dermatology
- Immune-related adverse events with immune checkpoint inhibitors in thoracic malignancies: focusing on non-small cell lung cancer patients
- (2018) Jordi Remon et al. Journal of Thoracic Disease
- Rare case of delayed onset colitis due to immunotherapy for malignant melanoma
- (2018) Mina Sarofim et al. ANZ JOURNAL OF SURGERY
- A phase II study investigating the safety and efficacy of neoadjuvant atezolizumab in muscle invasive bladder cancer (ABACUS).
- (2018) Thomas Powles et al. JOURNAL OF CLINICAL ONCOLOGY
- Preoperative pembrolizumab (pembro) before radical cystectomy (RC) for muscle-invasive urothelial bladder carcinoma (MIUC): Interim clinical and biomarker findings from the phase 2 PURE-01 study.
- (2018) Andrea Necchi et al. JOURNAL OF CLINICAL ONCOLOGY
- Clinical activity and safety of atezolizumab in patients with recurrent glioblastoma
- (2018) Rimas V. Lukas et al. JOURNAL OF NEURO-ONCOLOGY
- Camrelizumab (SHR-1210) alone or in combination with gemcitabine plus cisplatin for nasopharyngeal carcinoma: results from two single-arm, phase 1 trials
- (2018) Wenfeng Fang et al. LANCET ONCOLOGY
- Long-term Clinical Outcomes and Biomarker Analyses of Atezolizumab Therapy for Patients With Metastatic Triple-Negative Breast Cancer
- (2018) Leisha A. Emens et al. JAMA Oncology
- Neurologic immune-related adverse events associated with adjuvant ipilimumab: report of two cases
- (2018) Christine A. Garcia et al. Journal for ImmunoTherapy of Cancer
- Delayed onset of neurosarcoidosis after concurrent ipilimumab/nivolumab therapy
- (2018) Irena Tan et al. Journal for ImmunoTherapy of Cancer
- Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial
- (2018) Frank Stephen Hodi et al. LANCET ONCOLOGY
- The incidence and relative risk of pulmonary toxicity in patients treated with anti-PD1/PD-L1 therapy for solid tumors: a meta-analysis of current studies
- (2017) Chiara Ciccarese et al. Immunotherapy
- Efficacy and Safety Outcomes in Patients With Advanced Melanoma Who Discontinued Treatment With Nivolumab and Ipilimumab Because of Adverse Events: A Pooled Analysis of Randomized Phase II and III Trials
- (2017) Dirk Schadendorf et al. JOURNAL OF CLINICAL ONCOLOGY
- Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced Melanoma
- (2017) Jeffrey S. Weber et al. JOURNAL OF CLINICAL ONCOLOGY
- GR 02.04 Current Standard in Monitoring of Immunotherapy-Related Toxicity
- (2017) C. Mathias Journal of Thoracic Oncology
- Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006)
- (2017) Jacob Schachter et al. LANCET
- Late-onset nivolumab-mediated pneumonitis in a patient with melanoma and multiple immune-related adverse events
- (2017) Panagiotis T. Diamantopoulos et al. MELANOMA RESEARCH
- Is autoimmunity the Achilles' heel of cancer immunotherapy?
- (2017) Carl H June et al. NATURE MEDICINE
- Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma
- (2017) Jeffrey Weber et al. NEW ENGLAND JOURNAL OF MEDICINE
- Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
- (2017) Jedd D. Wolchok et al. NEW ENGLAND JOURNAL OF MEDICINE
- Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer
- (2017) Scott J. Antonia et al. NEW ENGLAND JOURNAL OF MEDICINE
- Immune-Related Adverse Effects of Cancer Immunotherapy— Implications for Rheumatology
- (2017) Laura C. Cappelli et al. RHEUMATIC DISEASE CLINICS OF NORTH AMERICA
- Immune-Related Adverse Events Associated with Anti-PD-1/PD-L1 Treatment for Malignancies: A Meta-Analysis
- (2017) Peng-Fei Wang et al. Frontiers in Pharmacology
- Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group
- (2017) I. Puzanov et al. Journal for ImmunoTherapy of Cancer
- Left Ventricular Dysfunction After Treatment With Ipilimumab for Metastatic Melanoma
- (2016) Mary E. Roth et al. AMERICAN JOURNAL OF THERAPEUTICS
- Management of toxicities of immune checkpoint inhibitors
- (2016) Lavinia Spain et al. CANCER TREATMENT REVIEWS
- Sequential administration of nivolumab and ipilimumab with a planned switch in patients with advanced melanoma (CheckMate 064): an open-label, randomised, phase 2 trial
- (2016) Jeffrey S Weber et al. LANCET ONCOLOGY
- Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial
- (2016) Howard L Kaufman et al. LANCET ONCOLOGY
- Bullous pemphigoid, an autoantibody-mediated disease, is a novel immune-related adverse event in patients treated with anti-programmed cell death 1 antibodies
- (2016) Shelley J.E. Hwang et al. MELANOMA RESEARCH
- The development of immunotherapy in older adults: New treatments, new toxicities?
- (2016) Carole Helissey et al. Journal of Geriatric Oncology
- Eosinophilic Fasciitis and Acute Encephalopathy Toxicity from Pembrolizumab Treatment of a Patient with Metastatic Melanoma
- (2016) L. Khoja et al. Cancer Immunology Research
- Late-onset pericardial tamponade, bilateral pleural effusions and recurrent immune monoarthritis induced by ipilimumab use for metastatic melanoma
- (2016) Constantin A Dasanu et al. JOURNAL OF ONCOLOGY PHARMACY PRACTICE
- Systematic review: colitis associated with anti-CTLA-4 therapy
- (2015) A. Gupta et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- A systematic review of immune-related adverse event reporting in clinical trials of immune checkpoint inhibitors
- (2015) T. W. Chen et al. ANNALS OF ONCOLOGY
- Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper
- (2015) S. Champiat et al. ANNALS OF ONCOLOGY
- Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis
- (2015) Anne Bertrand et al. BMC Medicine
- Phase II study of ipilimumab monotherapy in Japanese patients with advanced melanoma
- (2015) N. Yamazaki et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Increased treatment related toxicity subsequent to an anti-PD1 agent
- (2015) L. Khoja et al. Current Oncology
- Risk of cutaneous toxicities in patients with solid tumors treated with immune checkpoint inhibitors: a meta-analysis
- (2015) Omar Abdel-Rahman et al. Future Oncology
- Anti–PD-1–Related Pneumonitis during Cancer Immunotherapy
- (2015) Mizuki Nishino et al. NEW ENGLAND JOURNAL OF MEDICINE
- PD-1 pathway inhibitors: The next generation of immunotherapy for advanced melanoma
- (2015) Jason J. Luke et al. Oncotarget
- CTLA-4 blockade with ipilimumab: biology, safety, efficacy, and future considerations
- (2015) Luis H. Camacho Cancer Medicine
- Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab
- (2014) Suzanne L. Topalian et al. JOURNAL OF CLINICAL ONCOLOGY
- Efficacy and safety of ipilimumab in metastatic melanoma patients surviving more than 2 years following treatment in a phase III trial (MDX010-20)
- (2013) D. McDermott et al. ANNALS OF ONCOLOGY
- Phase I study of tremelimumab (CP-675 206) plus PF-3512676 (CPG 7909) in patients with melanoma or advanced solid tumours
- (2013) M Millward et al. BRITISH JOURNAL OF CANCER
- Brief S2k guidelines - Dermatofibrosarcoma protuberans
- (2013) Selma Ugurel et al. JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT
- Ipilimumab and Its Toxicities: A Multidisciplinary Approach
- (2013) L. A. Fecher et al. ONCOLOGIST
- Characteristics and management of immune-related adverse effects associated with ipilimumab, a new immunotherapy for metastatic melanoma
- (2012) Stephanie Andrews et al. Cancer Management and Research
- Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
- (2011) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates
- (2010) Julie R. Brahmer et al. JOURNAL OF CLINICAL ONCOLOGY
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- (2010) F. Stephen Hodi et al. NEW ENGLAND JOURNAL OF MEDICINE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started